Журнал исследований иммунологии слизистой оболочки

Абстрактный

Mucosal Autoimmune Disorders: Deciphering the Code

Nick J

Mucosal autoimmune disorders represent a complex and enigmatic group of diseases that afflict various mucosal surfaces within the human body, including the gastrointestinal tract, oral cavity, and respiratory system. These conditions, such as Crohn’s disease, ulcerative colitis, celiac disease, and oral lichen planus, share a common feature the immune system’s misguided attack on its own tissues, leading to chronic inflammation and tissue damage. This abstract provides an overview of the current state of knowledge regarding mucosal autoimmune disorders, with a focus on recent advancements in understanding their etiology, pathogenesis, and potential therapeutic strategies. Deciphering the code of mucosal autoimmune disorders involves unraveling the intricate interplay of genetic susceptibility, environmental triggers, and dysregulated immune responses. Genetic studies have identified numerous susceptibility loci associated with these conditions, shedding light on the genetic underpinnings of mucosal autoimmunity. Environmental factors, including diet, microbiota composition, and exposure to pathogens, have also been implicated in disease initiation and progression. The immune system’s role in mucosal autoimmunity is multifaceted, with both innate and adaptive immunity playing pivotal roles. Dysregulation of immune checkpoints, cytokine signaling pathways, and the gut-associated lymphoid tissue contributes to the perpetuation of chronic inflammation and tissue damage. Understanding these immune mechanisms is crucial for the development of targeted therapies. Recent advancements in the field of mucosal autoimmune disorders have brought forth promising therapeutic avenues. Biologic agents targeting specific immune pathways, such as anti-TNF-alpha and anti-IL-23 agents, have shown efficacy in managing diseases like Crohn’s disease and ulcerative colitis. Additionally, personalized medicine approaches, guided by genetic and immunological profiling, hold potential for tailoring treatments to individual patients.